Mineralys Therapeutics (NASDAQ:MLYS) Given “Outperform” Rating at Lifesci Capital

Lifesci Capital reissued their outperform rating on shares of Mineralys Therapeutics (NASDAQ:MLYS) in a research note published on Tuesday, Zacks.com reports. Lifesci Capital also issued estimates for Mineralys Therapeutics’ FY2024 earnings at ($2.04) EPS.

Mineralys Therapeutics Trading Down 0.5 %

Shares of NASDAQ MLYS opened at $12.78 on Tuesday. Mineralys Therapeutics has a 12-month low of $5.85 and a 12-month high of $17.70. The firm has a 50 day moving average of $13.17 and a 200 day moving average of $10.10. The firm has a market capitalization of $634.27 million and a price-to-earnings ratio of -6.39.

Mineralys Therapeutics (NASDAQ:MLYS) last posted its quarterly earnings results on Thursday, March 21st. The company reported ($0.61) EPS for the quarter, beating analysts’ consensus estimates of ($0.85) by $0.24. Sell-side analysts predict that Mineralys Therapeutics will post -2.64 EPS for the current year.

Insider Activity

In other news, major shareholder Samsara Biocapital Gp, Llc purchased 555,555 shares of the company’s stock in a transaction that occurred on Monday, February 12th. The stock was purchased at an average cost of $13.50 per share, with a total value of $7,499,992.50. Following the purchase, the insider now owns 5,074,916 shares in the company, valued at $68,511,366. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website.

Hedge Funds Weigh In On Mineralys Therapeutics

Several institutional investors have recently made changes to their positions in the company. CWM LLC acquired a new stake in Mineralys Therapeutics in the third quarter valued at approximately $25,000. New York State Common Retirement Fund acquired a new position in shares of Mineralys Therapeutics during the 1st quarter worth about $53,000. PNC Financial Services Group Inc. increased its stake in Mineralys Therapeutics by 17,821.7% during the 4th quarter. PNC Financial Services Group Inc. now owns 4,122 shares of the company’s stock worth $35,000 after buying an additional 4,099 shares in the last quarter. Citigroup Inc. acquired a new position in Mineralys Therapeutics in the 2nd quarter valued at $71,000. Finally, California State Teachers Retirement System purchased a new position in Mineralys Therapeutics in the 1st quarter valued at $70,000. 84.46% of the stock is owned by hedge funds and other institutional investors.

About Mineralys Therapeutics

Mineralys Therapeutics, Inc, a clinical-stage biopharmaceutical company that develops therapies for the treatment of hypertension and associated cardiovascular diseases. It clinical-stage product candidate is lorundrostat, a proprietary, orally administered, highly selective aldosterone synthase inhibitor for the treatment of patients with uncontrolled or resistant hypertension.